Nattokinase has been demonstrated to improve the Aβ-induced cognitive impairment, as well as anxiety-, depression-like behavior in mouse models of AD, possibly via the downregulation of the pro-inflammatory cytokines IL-6 and TNF-α, as well as the upregulation BDNF and the anti-inflammatory cytokine Il-10 [123].These findings suggest that these agents might hold a promising therapeutic potential in MBI and especially the domains of affective dysregulation and apathy in AD, mainly through their effects on the HPA axis regulation and neuroinflammatory responses. This evidence concerns the gene IL6 and Alzheimer disease.